Similarly, alterations in RAS in AML/MDS are heterogeneous, differentially impact outcomes, and are likely influenced by the presence of concurrent mutations such as BCOR, leading to resistance to chemotherapy, venetoclax, azacitidine, and targeted therapy such as tyrosine kinase and FLT3 inhibitors [40,41]. The gene discussed is BCOR; the disease is myelodysplastic syndrome.